Nektar Therapeutics (0UNL.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 709.93M |
| Enterprise Value | 843.72M |
| P/E Ratio | -6.5 |
| PEG Ratio | -0.68 |
| Price/Sales Ratio | 22.9 |
| Price/Book Ratio | 1.6 |
| Enterprise/Revenue | 24.68 |
| Enterprise/EBITDA | -10.02 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
Profitability
| Profit Margin | -2.88 |
| Operating Margin | -2.4 |
AD
Management Effectiveness
| Return On Assets | -0.14 |
| Return On Equity | -0.38 |
Income Statement
| Revenue | 55.23M |
| Revenue/Share | 1.65 |
| Gross Profit | 54.21M |
| EBITDA | -133.45M |
| Net Income | -164.08M |
| Diluted EPS | -9.73 |
Balance Sheet
| Total Cash | 684.34M |
| Total Cash/Share | 20.7 |
| Total Debt | 135.93M |
| Total Debt/Equity | 0.15 |
| Current Ratio | 10.42 |
| Book Value Per Share | 27.32 |
Price History
| 52-Week Change | -25.83 |
| 52-Week High | 106 |
| 52-Week Low | 33 |
| Moving Average 50 Days | 70.04 |
| Moving Average 200 Days | 65.12 |
Statistics
| Average Volume | 1,466 |
| Shares Outstanding | 19.54M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
